ArticleNature medicine2019
A selective BCL-X
Registry-linked trialAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04886622 (A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies), which is not on this map. Cited by 364 papers.
0numbers the graph read from it
0cells of the map it votes in
364citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
Who cites it
364 citing papers in PubMed.
- Hepatocyte senescence in metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology communications · 2026Review
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems.Acta pharmacologica Sinica · 2026Review
- Genome-wide CRISPR screens identify an RXR-MYLIP-LDLR axis regulating BH3 mimetic sensitivity in peripheral T-cell lymphomas.Oncogene · 2026Article
- Cellular senescence and regulated cell death in cancer: mechanisms, cross-regulatory networks and therapeutic implications.Journal of hematology & oncology · 2026Review
- Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.Biomarker research · 2026Review
- Nanotechnology-Enabled Targeted Protein Degradation: Strategies, Opportunities, and Challenges.Small methods · 2026Review
- PROTAC-mediated targeting of IKKβ and NR4A1 for AML therapy.Oncogene · 2026Article
- De Novo-Designed Bifunctional Proteins for Targeted Protein Degradation.Journal of the American Chemical Society · 2026Article
- Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance.NPJ precision oncology · 2026Article
- Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma.Molecular cancer therapeutics · 2026Review
- Article
- Dual targeting of BCL-XL and MCL-1 exposes a rapid and exploitable apoptotic vulnerability in non-small cell lung cancer.Cell death and differentiation · 2026Article
- BH3 profiling analyses for functional precision medicine.Oncogenesis · 2026Review
- Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeting E3 ubiquitin ligases: Mechanistic breakthroughs and novel clinical translation pathways for tumor radioimmunotherapy.Molecular cancer · 2026Review
- Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review.Pharmaceutics · 2026Review
- A peptide-based screen for cell death inhibitors identifies the cytoprotective compound CDL36.bioRxiv : the preprint server for biology · 2026Article
- Identification of Clofibric Acid as a Synoviolin (SYVN1) Ligand for Proteolysis-Targeting Chimera (PROTAC) Development.ACS medicinal chemistry letters · 2026Article
- Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2.Journal of medicinal chemistry · 2026Article
- Targeted protein degradation: bridging chemical biology and clinical translation.Acta pharmacologica Sinica · 2026Review
304 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Sajid Khan *Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Xuan Zhang *Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0001-6062-6708
Dongwen Lv *Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-4677-8996
Qi ZhangDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Yonghan HeDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Peiyi ZhangDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Xingui LiuDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Dinesh ThummuriDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Yaxia YuanDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Janet S WiegandDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Jing PeiDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Weizhou ZhangDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
Abhisheak SharmaDepartment of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, USA.ORCID http://orcid.org/0000-0003-0553-4039
Christopher R McCurdyDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Vinitha M KuruvillaDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Natalia BaranDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-0618-4798
Adolfo A FerrandoDepartment of Pediatrics, Pathology, Cell Biology and Systems of Biology and Institute for Cancer Genetics, Columbia University, New York, NY, USA.
Yong-Mi KimDepartment of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Anna RogojinaGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Peter J HoughtonGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Guangcun HuangDepartment of Medicine, the Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0003-1695-1153
Robert HromasDepartment of Medicine, the Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Marina KonoplevaDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Guangrong ZhengDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA. zhengg@cop.ufl.edu.ORCID http://orcid.org/0000-0002-8106-6663
Daohong ZhouDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA. zhoudaohong@cop.ufl.edu.ORCID http://orcid.org/0000-0002-2400-6461
Funding
Molecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7MEEPD1 Repair of Stressed Replication ForksR01CA205224 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robert A Hromas · 2016 to 2026
$3.3MUse of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancerR01CA242003 · NCI · UNIVERSITY OF FLORIDA · PI TREVINO, JOSE G., ZHENG, GUANGRONG · 2019 to 2023
$2.6MRole of Senescent Cells in Radiation-induced Pulmonary FibrosisR01CA219836 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI ZHOU, DAOHONG · 2017 to 2021
$1.8MIonizing radiation induced hematological malignanciesR01CA211963 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI ZHOU, DAOHONG · 2017 to 2021
$1.8MObesity, inflammation and breast cancerR01CA200673 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7MCD177 suppresses breast-cancer development by inhibiting beta-cateninR01CA203834 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7MMechanisms for Chromosomal TranslocationsR01GM109645 · NIGMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HROMAS, ROBERT A · 2015 to 2018
$1.2MNCI Clinical and Translational Exploratory/ Developmental StudiesR21CA223371 · NCI · UNIVERSITY OF FLORIDA · PI ZHENG, GUANGRONG · 2018 to 2019
$359kNCI NIH HHS R01 CA200673NCI NIH HHS R01 CA203834NCI NIH HHS R01 CA205224NCI NIH HHS R01 CA211963NCI NIH HHS R01 CA219836NCI NIH HHS R01 CA242003NCI NIH HHS R21 CA223371NCI NIH HHS R35 CA210065NIGMS NIH HHS R01 GM109645
Abstract
B-cell lymphoma extra large (BCL-X
Indexed as
Aniline CompoundsAnimalsAntineoplastic Agentsbcl-X ProteinBlood PlateletsGene Expression Regulation, NeoplasticHeterograftsHumansMiceProteolysisSulfonamidesThrombocytopeniaVon Hippel-Lindau Tumor Suppressor ProteinAniline CompoundsAntineoplastic AgentsBCL2L1 protein, humanbcl-X ProteinnavitoclaxSulfonamidesVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04886622ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.